|
English
|
正體中文
|
简体中文
|
总笔数 :2856704
|
|
造访人次 :
53716816
在线人数 :
939
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"hsieh e f"的相关文件
显示项目 1-10 / 11 (共2页)
1 2 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2021-12-02T05:41:26Z |
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC[sbnd]COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
|
Hsieh S.-M.; WANG-DA LIU; Huang Y.-S.; Lin Y.-J.; Hsieh E.-F.; Lian W.-C.; Chen C.; Janssen R.; Shih S.-R.; Huang C.-G.; Tai I.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-24T08:23:28Z |
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC[sbnd]COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
|
Hsieh S.-M.; Liu W.-D.; YU-SHAN HUANG; Lin Y.-J.; Hsieh E.-F.; Lian W.-C.; Chen C.; Janssen R.; Shih S.-R.; Huang C.-G.; Tai I.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-20T07:38:57Z |
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC[sbnd]COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
|
SZU-MIN HSIEH; Liu W.-D.; Huang Y.-S.; Lin Y.-J.; Hsieh E.-F.; Lian W.-C.; Chen C.; Janssen R.; Shih S.-R.; Huang C.-G.; Tai I.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-20T04:24:49Z |
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC[sbnd]COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
|
Hsieh S.-M.; Liu W.-D.; Huang Y.-S.; Lin Y.-J.; Hsieh E.-F.; Lian W.-C.; Chen C.; Janssen R.; Shih S.-R.; Huang C.-G.; Tai I.-C.; SHAN-CHWEN CHANG |
| 臺大學術典藏 |
2021-08-16T08:36:14Z |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
|
ARISTINE CHENG; Hsieh S.-M.; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; Chang S.-C. |
| 臺大學術典藏 |
2021-06-24T07:16:12Z |
Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan
|
Li-Min Huang;Chiu C.-H.;Chiu N.-C.;Lin C.-Y.;Li M.-T.;Kuo T.-Y.;Weng Y.-J.;Hsieh E.-F.;Tai I.-C.; LI-MIN HUANG; Chiu C.-H.; Chiu N.-C.; Lin C.-Y.; Li M.-T.; Kuo T.-Y.; Weng Y.-J.; Hsieh E.-F.; Tai I.-C. |
| 臺大學術典藏 |
2021-06-24T07:16:12Z |
Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan
|
Li-Min Huang;Chiu C.-H.;Chiu N.-C.;Lin C.-Y.;Li M.-T.;Kuo T.-Y.;Weng Y.-J.;Hsieh E.-F.;Tai I.-C.; LI-MIN HUANG; Chiu C.-H.; Chiu N.-C.; Lin C.-Y.; Li M.-T.; Kuo T.-Y.; Weng Y.-J.; Hsieh E.-F.; Tai I.-C. |
| 臺大學術典藏 |
2020-12-30T02:44:11Z |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
|
Cheng A.; Hsieh S.-M.; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; SHAN-CHWEN CHANG |
| 臺大學術典藏 |
2020-12-29T06:37:34Z |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
|
Shi-Chung Chang S.; Lai K.-L.; Chen C.; Lee H.-C.; Lin T.-W.; Hsieh E.-F.; Li Y.-H.; Pan S.-C.; Cheng A.; SZU-MIN HSIEH; Chang S.-C. |
| 臺大學術典藏 |
2020-09-30T02:30:08Z |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
|
Cheng A.;Hsieh S.-M.;Sung-Ching Pan;Li Y.-H.;Hsieh E.-F.;Lee H.-C.;Lin T.-W.;Lai K.-L.;Chen C.;Shi-Chung Chang S.;Chang S.-C.; Cheng A.; Hsieh S.-M.; SUNG-CHING PAN; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Shi-Chung Chang S.; Chang S.-C.; Chen C. |
显示项目 1-10 / 11 (共2页)
1 2 > >>
每页显示[10|25|50]项目
|
